Brought to you by 
Trius partners antibiotic torezolid with Bayer in emerging markets
23 Jun 2014
Executive Summary
Trius Therapeutics Inc. (infectious diseases) has exclusively licensed Bayer HealthCare Pharmaceuticals AG its lead Phase III antibiotic torezolid (formerly TR701) to sell in China, Japan, and all of Asia (excluding North and South Korea), plus Africa, Latin America, and the Middle East.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Trius partners antibiotic torezolid with Bayer in emerging markets
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice